medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Number 5

<< Back Next >>

Rev Invest Clin 2005; 57 (5)

Bioterrorism agents: getting ready for the unthinkable

Franco-Paredes C, Rodríguez-Morales A, Santos-Preciado JI

Language: Spanish
References: 96
Page: 695-705
PDF size: 85.27 Kb.


ABSTRACT

The September 11, 2001 terrorist attacks in the USA demonstrated our vulnerability to terrorist raids. Furthermore, in the same year inhalational anthrax cases in humans caused by the international release of Bacillus anthracis spores via the USA postal system inflicted a lot of panic and terror over the civilian population. The succeeding terrorist events scattered in several other countries are continous reminders of our failness and of the risk that terrorists attempts in the future may be implemented by means of deliberate evil release of biological agents. These events may be perpetrated by either the release of an infectious agent or any of its products in order to spread death or sickness in humans, animals, or plants with the obnoxius purpose of scaring governments and societies for the profit of particular ideological causes. In the current article, we present a review of the main bioterrorism agents, as well as a historical and clinical aspects and their significance for public health preparedness and response.


REFERENCES

  1. Varkey P, Poland GA, Cockerill F, et al. Confronting bioterrorism. Physicians on the front line. Mayo Clin Proceed 2002; 77: 661-72.

  2. Lane CH, Fauci AS. Bioterrorism on the home front. A new challenge for American medicine. JAMA 2001; 286(20): 2597-9.

  3. Del Rio C, Franco-Paredes C. Bioterrorismo: Un nuevo problema de salud pública. Sal Pub Méx 2001; 43(6): 585-8.

  4. CDC. Recognition of illness associated with the intentional release of a biologic agent. MMWR 2001; 50(41): 893-7.

  5. Borio L, Frank D, Venkat M, et al. Death due to bioterrorism-related inhalational anthrax. Report of 2 patients. JAMA 2001; 286(20): 2554-9.

  6. Jeringan J, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001; 7(6): 1-26. Versión electrónica: http://www.cdc.gov/ncidod/EID/vol7no6/jernigan.htm

  7. Quintilliani R Jr, Majan AK, Quintilliani R. Fatal case of inhalational anthrax mimicking intra-abdominal sepsis. Clin Infect Dis 2001; 33. Versión electrónica: http://www.emory.edu/ID/011434.web.pdf

  8. Mina B, Dym J, Kuepper F, et al. Fatal inhalational anthrax with unknown source of exposure in a 61-year-old woman in New York City. JAMA 2002; 287: 858-62.

  9. Barakat L, Quentzel H, Jeringan J, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002; 287; 863-8.

  10. Sundelius B, Gronvall J. Strategic dilemmas of biosecurity in the European Union. Biosecurity and Bioterrorism 2004; 2(10): 17-23.

  11. Christopher G, Cieslak T, Pavlin J, et al. Biological warfare: A historical perspective. JAMA 1997; 278(5): 412-17.

  12. McNeill WH. Plagues and People. Garden City, NY: Anchor Press/Doubleday; 1976.

  13. Diamond J. Up to the starting line. In: Guns, Germs, Steel. The fates of human societies. New York (NY): WW Norton and Company; 1999, p. 35-52.

  14. Giesecke J. Mathematical models for epidemics. In: Modern Infectious Disease Epidemiology. Oxford: University Press; 1994, p. 109-23.

  15. Van Courtland Moon JE. The Korean war case. Ann NY Acad Sci 1992; 666: 53-83.

  16. Inglesby T, Henderson T, Bartlett JG, et al. Anthrax as a biological weapon. Medical and public health management. JAMA 1999; 281(18): 1735-45.

  17. Meselson M, Gullemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266: 1202-8.

  18. Simon JD. Biological terrorism: preparing to meet the threat. JAMA 1997; 278(5): 428-30.

  19. Torok TJ, Tauxe RV, Wise R, et al. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 1997; 278(5): 389-95.

  20. WuDunn S, Miller J, Broad W. How Japan germ terror alerted world. New York Times, May 26, 1998: 1-6.

  21. Henderson DA, Moss B. Smallpox and vaccinia. In: Plotkin SA, Orenstein WA (Ed.). Vaccines (3rd. edition). Philadelphia, PA: W.B. Saunders; 1999, p. 74-97.

  22. Fenner F, Henderson DA, Arita I, et al (Eds.). Smallpox and it’s eradication. Geneva: World Health Organization; 1988, Available from the WHO website at: http://www.who.int/emc/diseases/smallpox/Smallpoxeradication.htm

  23. Hopkins DR. Princes and Peasants. Smallpox in History. Chicago: University of Chicago Press; 1983.

  24. Barquet N, Domingo P. Smallpox: The triumph over the most terrible of the ministers of death. Ann Intern Med 1997; 127: 635-42.

  25. Henderson DA, Inglesby TV, Bartlett JG, et al. Working Group on Civilian Biodefense: Smallpox as a biological weapon: medical and public Health management. JAMA 1999; 281: 2127-37.

  26. Ferguson NM, Keeling MJ, Edmunds JW, et al. Planning for smallpox outbreaks. Nature 2003; 425: 681-5.

  27. Bray M, Buller M. Looking back at smallpox. Clin Infect Dis 2004; 38: 882-9.

  28. Centers for Disease Control. Strengthening national preparedness for smallpox: An update. Emerg Infect Dis 2001; 7(1): 155-6.

  29. CDC. Vaccinia (smallpox) vaccine. Recommendations of the Advisory Committee on Immunizations Practices (ACIP). MMWR 2001; 50(RR-10): 1-25.

  30. Henderson DA. Countering the post eradication threat of smallpox and polio. Clin Infect Dis 2002; 34: 79-83.

  31. Mack TM. Smallpox in Europe, 1950-1971. J Infect Dis 1972; 125: 161-9.

  32. Mack T. A different view of smallpox and vaccination. N Engl J Med 2003; 348(5): 460-3.

  33. World Health Organization. The global eradication of smallpox. Final report of the global commission for the certification of smallpox eradication. In: History of International Public Health No. 4. Geneva: World Health Organization; 1980.

  34. Schraeder TL, Campion EW. Smallpox vaccination-The call to arms. N Engl J Med 2003; 348(5): 381-2.

  35. Henderson DA, Fenner F. Recent events and observations pertaining to smallpox virus destruction in 2002. Clin Infect Dis 2001; 33: 1057-9.

  36. WHO. Smallpox eradication: temporary retention of Variola virus stocks. Weekly Epidem Record 2001; 19: 142-5.

  37. Lane JM, Goldstein J. Evaluation of 21st century risks of smallpox vaccination and policy options. Ann Intern Med 2003; 138: 488-93.

  38. O’Toole T. Smallpox: An attack scenario. Emerg Infect Dis 1999; 5(4): 540-51.

  39. Rosenthal SR, Merchlinsky M, Kleppinger C, et al. Developing new smallpox vaccines. Emerg Infect Dis 2001; 7.

  40. Mortimer P. Can Post exposure prophylaxis vaccination against smallpox succeed? Clin Infect Dis 2003; 36: 622-9.

  41. Lane JM, Ruben FL, Neff JM, et al. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis 1970; 122: 303-9.

  42. Bartlett J, Borio L, Radonovich L, et al. Smallpox vaccination in 2003: key information for clinicians. Clin Infect Dis 2003; 36: 883-900.

  43. Blendon RJ, DesRoches C, Benson JM, et al. The public and the smallpox threat. N Engl J Med 2003; 348(5): 426-32.

  44. Sepkowitz KA. How contagious is vaccinia? N Engl J Med 2003; 348(5): 439-46.

  45. Breman JG, Henderson DA. Poxvirus dilemmas: monkepox, smallpox, and biological terrorism. N Engl J Med 1998; 339: 556-9.

  46. Halloran ME, Longini IM, Nizam A, et al. Containing bioterrorist smallpox. Science 2002; 15(298): 1428-32.

  47. Bozzette S, Boer B, Bhatnagar V, et al. A model for a smallpox-vaccination policy. N Engl J Med 2003; 348(5): 416-25.

  48. Metlzer MI, Damon I, LeDuc JW, et al. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg Infect Dis 2001; 7(6): 1-19.

  49. Fukao T. Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity. Lancet Infect Dis 2004; 4: 167-70.

  50. Zilinskas RA. Iraq’s biological weapons: the past as future? JAMA 1997; 278(5): 418-24.

  51. Amon S, Schechter R, Inglesby T, et al. Botulinum toxin as a biological weapon. Medical and public health management. JAMA 2001; 285(8): 1059-70.

  52. Dowell VR JR, McCroskey LM, Hatheway CL, et al. Coproexamination for botulinum toxin and clostridium botulinum: a new procedure for laboratory diagnosis of botulism. JAMA 1977; 238: 1829-32.

  53. Khan AS, Swerdlow DL, Juranek DD. Precautions against biological and chemical terrorism directed at food and water supplies. Public Health Rep 2001; 116: 3-14.

  54. Inglesby T, Dennis D, Henderson D, et al. Plague as a biological weapon. Medical and public health management. JAMA 2000; 283: 2281-90.

  55. Perry RD, Fetherston JD. Yersinia pestis –etiologic agent of plague. Clin Microbiol Rev 1997; 10: 35-66.

  56. Slack P. The Black Death past and present. Trans R Soc Trop Med Hyg 1989; 83: 461-3.

  57. Derbes VJ. De Mussis and the great plague of 1349: A forgotten episode of bacteriological war. JAMA 1966; 196: 59-62.

  58. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM Jr. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399-411.

  59. Zietz BP, Dunkelberg H. The history of the plague and the research on the causative agent Yersinia pestis. Int J Hyg Environ Health 2004; 207: 165-78.

  60. Josko D. Yersinia pestis: still a plague in the 21st century. Clin Lab Sci 2004; 17: 25-9.

  61. Kohler W, Kohler M. Plague and rats, the “plague of the Philistines”, and: what did our ancestors know about the role of rats in plague. Int J Med Microbiol 2003; 293: 333-40.

  62. Greenfield RA, Bronze MS. Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents. Drug Discov Today 2003; 8: 881-8.

  63. Dennis DT, Inglesby T, Henderson T, et al. Tularemia as a biological weapon. Medical and public health management. JAMA 2001; 285(21): 2763-73.

  64. Borio L, Inglesby T, Peters CJ. Hemorrhagic fever viruses as biological weapons: Medical and public health management. JAMA 2002: 287(18): 2391-2405.

  65. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 1987; 155: 456-64.

  66. McCormick JB, King IJ, Webb PA, Johnson KM, O’Sullivan R, Smith ES, Trippel S, Tong TC. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 1987; 155: 445-55.

  67. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 1987; 155: 437-44.

  68. Enria D, Franco SG, Ambrosio A, Vallejos D, Levis S, Maiztegui J. Current status of the treatment of Argentine Hemorrhagic Fever. Med Microbiol Immunol (Berl.) 1986; 175: 173-6.

  69. Kenyon RH, McKee KT Jr, Maiztegui JI, Green DE, Peters CJ. Heterogeneity of Junin virus strains. Med Microbiol Immunol (Berl.) 1986; 175: 169-72.

  70. Maiztegui J, Feuillade M, Briggiler A. Progressive extension of the endemic area and changing incidence of Argentine Hemorrhagic Fever. Med Microbiol Immunol (Berl) 1986; 175: 149-52.

  71. Ambrosio AM, Enria DA, Maiztegui JI. Junin virus isolation from lympho-mononuclear cells of patients with Argentine hemorrhagic fever. Intervirology 1986; 25: 97-102.

  72. Johnson KM, Mackenzie RB, Webb PA, Kuns ML. Chronic infection of rodents by Machupo virus. Science 1965; 150: 1618-9.

  73. Mackenzie RB, Webb PA, Johnson KM. Detection of complement-fixing antibody after Bolivian hemorrhagic fever, employing Machupo, Junin and Tacaribe virus antigens. Am J Trop Med Hyg 1965; 14: 1079-84.

  74. Johnson KM. Epidemiology of Machupo virus infection. 3. Significance of virological observations in man and animals. Am J Trop Med Hyg 1965; 14: 816-8.

  75. Johnson KM, Wiebenga NH, Mackenzie RB, Kuns Ml, Tauraso NM, Shelokov A, Webb PA, Justines G, Beye HK. Virus isolations from human cases of hemorrhagic fever in Bolivia. Proc Soc Exp Biol Med 1965; 118: 113-8.

  76. Salas R, de Manzione N, Tesh RB, Rico-Hesse R, Shope RE, Betancourt A, Godoy O, Bruzual R, Pacheco ME, Ramos B. Venezuelan hemorrhagic fever. Lancet 1991; 338: 1033-6.

  77. Tesh RB, Jahrling PB, Salas R, Shope RE. Description of Guanarito virus (Arenaviridae: Arenavirus), the etiologic agent of Venezuelan hemorrhagic fever. Am J Trop Med Hyg 1994; 50: 452-9.

  78. de Manzione N, Salas RA, Paredes H, Godoy O, Rojas L, Araoz F, Fulhorst CF, Ksiazek TG, Mills JN, Ellis BA, Peters CJ, Tesh RB. Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clin Infect Dis 1998; 26: 308-13.

  79. Weaver SC, Salas RA, de Manzione N, Fulhorst CF, Duno G, Utrera A, Mills JN, Ksiazek TG, Tovar D, Tesh RB. Guanarito virus (Arenaviridae) isolates from endemic and outlying localities in Venezuela: sequence comparisons among and within strains isolated from Venezuelan hemorrhagic fever patients and rodents. Virology 2000; 266: 189-95.

  80. Gonzalez JP, Bowen MD, Nichol ST, Rico-Hesse R. Genetic characterization and phylogeny of Sabia virus, an emergent pathogen in Brazil. Virology 1996; 221: 318-24.

  81. Lisieux T, Coimbra M, Nassar ES, Burattini MN, de Souza LT, Ferreira I, Rocco IM, da Rosa AP, Vasconcelos PF, Pinheiro FP, et al. New Arenavirus isolated in Brazil. Lancet 1994; 343: 391-2.

  82. Easterday BC. Rift valley fever. Adv Vet Sci 1965; 10: 65-127.

  83. Davies FG, Kilelu E, Linthicum KJ, Pegram RG. Patterns of Rift Valley fever activity in Zambia. Epidemiol Infect 1992; 108: 185-91.

  84. van Eeden PJ, Joubert JR, van de Wal BW, King JB, de Kock A, Groenewald JH. A nosocomial outbreak of Crimean-Congo hemorrhagic fever at Tygerberg Hospital. Part I. Clinical features. S Afr Med J 1985; 68: 711-7.

  85. van Eeden PJ, van Eeden SF, Joubert JR, King JB, van de Wal BW, Michell WL. A nosocomial outbreak of Crimean-Congo hemorrhagic fever at Tygerberg Hospital. Part II. Management of patients. S Afr Med J 1985; 68: 718-21.

  86. Malherbe H, Strickland-Cholmley M. Human disease from monkeys (Marburg virus). Lancet 1968; 1: 1434.

  87. Shu HL, Siegert R, Slenczka W. The pathogenesis and epidemiology of the “Marburg-virus” infection. Ger Med Mon 1969; 14: 7-10.

  88. World Health Organization. Ebola hemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56: 271-93.

  89. World Health Organization. Ebola hemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 1978; 56: 247-70.

  90. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani AM, Al-Sayed MO, Abodahish AA, Khan AS, Ksiazek TG, Shobokshi O. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003; 37: 1084-92.

  91. Athar MN, Baqai HZ, Ahmad M, Khalid MA, Bashir N, Ahmad AM, Balouch AH, Bashir K. Short report: Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002. Am J Trop Med Hyg 2003; 69: 284-7.

  92. Bray M. Defense against filoviruses used as biological weapons. Antiviral Res 2003; 57: 53-60.

  93. Straight TM, Lazarus AL, Decker CF. Defending against viruses in biowarfare. Postgrad Med 2002; 2: 75.

  94. Miller J, Engelberg S, Broad WJ. Germs: Biological Weapons and America’s secret war. Waterville, Me: GK Hall; 2002.

  95. Alibek K, Handelman S. Biohazard: The chilling trues story of the largest covert biological weapons program in the world, told from the inside by the man who ran it. New York, NY: Random House; 1999.

  96. Danzig R, Berkowsky PB. Why should we be concerned about biological warfare? JAMA 1997: 278(5): 431-2.




2020     |     www.medigraphic.com